Aim: Given the adverse effects of anticholinergic drugs and the necessity for medication evaluation tools in the aging population, a comprehensive scale to assess the total anticholinergic burden in Japan was developed. We examined the longitudinal association between the anticholinergic burden, quantified using the Japanese Anticholinergic Drug Risk Scale, and the development of frailty and sarcopenia in older adults.

Methods: In this longitudinal population-based cohort study, 2044 older residents without long-term care needs were randomly selected from a community in Kashiwa, Japan. Baseline data were collected in 2012, with follow-ups in 2013, 2014, 2016, 2018, and 2021. Medications were identified through interviews and assessed with the Screening Tool for Older Persons' Appropriate Prescriptions for the Japanese. The anticholinergic burden was quantified using the Japanese Anticholinergic Risk Scale. We evaluated new-onset frailty and sarcopenia using the Cardiovascular Health Study Index and Asian Working Group for Sarcopenia 2019 criteria, respectively.

Results: Of the 1549 participants without sarcopenia or frailty at baseline (age 72.5 ± 5.5 years; 49.1% women; median follow-up 6.0 years), 274 and 230 developed new-onset frailty and sarcopenia, respectively, during follow-up. After adjusting for potential confounders, an anticholinergic burden score ≥3 was strongly associated with new-onset frailty and sarcopenia (adjusted hazard ratio [95% confidence interval]: 2.45 [1.52-3.94] and 2.01 [1.20-3.35], respectively).

Conclusions: Anticholinergic burden is a predictor of frailty and sarcopenia in community-dwelling older adults. Effective evaluation and management of anticholinergic burden using the Japanese Anticholinergic Drug Risk Scale are crucial for promoting healthy aging and mitigating adverse health outcomes. Geriatr Gerontol Int 2025; ••: ••-••.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ggi.70012DOI Listing

Publication Analysis

Top Keywords

anticholinergic burden
28
frailty sarcopenia
24
risk scale
16
japanese anticholinergic
16
burden quantified
12
quantified japanese
12
new-onset frailty
12
anticholinergic
11
predictor frailty
8
sarcopenia
8

Similar Publications

Objectives: Malnutrition is common in dementia patients and can lead to poor outcomes. Also, these patients are often prescribed medications with sedative and anticholinergic effects for various reasons. Thus, we aimed to explore the relationship between drug burden index (DBI), anticholinergic burden (ACB), and nutrition status in community-dwelling older adults with dementia.

View Article and Find Full Text PDF

Objectives: Anticholinergic medications can produce harmful side effects, such as ataxia and delirium, in older adults. Older adults with hip fractures are particularly vulnerable, yet they are often prescribed these medications. This study aimed to evaluate the anticholinergic burden (ACB) before and after hospitalization for hip fracture, to identify potential targets for deprescribing.

View Article and Find Full Text PDF

Aim: Given the adverse effects of anticholinergic drugs and the necessity for medication evaluation tools in the aging population, a comprehensive scale to assess the total anticholinergic burden in Japan was developed. We examined the longitudinal association between the anticholinergic burden, quantified using the Japanese Anticholinergic Drug Risk Scale, and the development of frailty and sarcopenia in older adults.

Methods: In this longitudinal population-based cohort study, 2044 older residents without long-term care needs were randomly selected from a community in Kashiwa, Japan.

View Article and Find Full Text PDF

Background: In clinical studies of older adults, polypharmacy (use of ≥ 5 drugs) and the Drug Burden Index (DBI; measures exposure to anticholinergic and sedative drugs) are associated with impaired physical function and frailty. We used computational video analysis of aging mice to examine the impact of medications on morphometric and gait function.

Methods: Middle-aged (12 month) male mice were administered therapeutic doses of medications in polypharmacy regimens with different DBI scores or monotherapy with medications from the High DBI polypharmacy regimen.

View Article and Find Full Text PDF

Background: Because of their high prevalence, chronic respiratory diseases, like asthma and chronic obstructive pulmonary disease, represent main public health problems. They are mainly treated through inhaled therapy. There is low adherence to such therapy, resulting in poor control of chronic respiratory diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!